Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High-Grade vs Low-Grade Serous Ovarian Ca Outcomes

Obstet Gynecol; ePub 2017 Feb 6; Gockley, et al

Low-grade serous ovarian cancer is associated with improved survival compared with high-grade serous ovarian cancer, a recent study found. The retrospective study included patients diagnosed with grade 1 or 3, advanced-stage serous ovarian cancer between 2003 and 2011. Researchers found:

  • 16,854 patients with high-grade serous ovarian cancer and 755 patients with low-grade serous ovarian cancer were identified.
  • Median overall survival was 40.7 months among high-grade patients and 90.0 months among women with low-grade tumors.
  • Lymphadenectomy, but not adjuvant chemotherapy, was associated with improved survival in those with advanced-stage low-grade serous ovarian cancer.

Citation:

Gockley A, Melamed A, Bregar AJ, et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. [Published online ahead of print February 6, 2017]. Obstet Gynecol. doi:10.1097/AOG.0000000000001867.